RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform

Hwang, Beom Jeung; Jang, Yohan; Kwon, Soon Bin; Yu, Ji Eun; Lim, Jongkwan; Roh, Young Hoon; Seong, Baik Lin

doi:10.1016/j.biomaterials.2021.120650

Cited by 18 publications

(20 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, the capsid proteins of non-enveloped, single-capsid VLPs can be assembled in a cell-free environment to form homogenous VLPs [75] , [76] , [77] , or synthesized and assembled in an entirely cell-free environment [78] , [79] . In one such system based on purified components, VLP precursors or capsomeres are expressed in E. coli , purified from host contaminants, and assembled into VLPs in a cell-free in vitro environment.…”

Section: Vlp Expression Systems and Resultant Vaccination Efficacymentioning

confidence: 99%

Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic

Zhao

Huang

et al. 2022

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nano-scale particles that are morphologically similar to a live virus but which lack a genetic component. Since the pandemic spread of COVID-19, much focus has been placed on coronavirus (CoV)-related VLPs. CoVs contain four structural proteins, though the minimum requirement for VLP formation differs among virus species. CoV VLPs are commonly produced in mammalian and insect cell systems, sometimes in the form of chimeric VLPs that enable surface display of CoV epitopes. VLPs are an ideal model for virological research and have been applied as vaccines and diagnostic reagents to aid in clinical disease control. This review summarizes and updates the research progress on the characteristics of VLPs from different known CoVs, mainly focusing on assembly, in vitro expression systems for VLP generation, VLP chimerism, protein-based nanoparticles and their applications in basic research and clinical settings, which may aid in development of novel VLP vaccines against emerging coronavirus diseases such as SARS-CoV-2.

show abstract

Section: Vlp Expression Systems and Resultant Vaccination Efficacymentioning

confidence: 99%

Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic

Zhao

Huang

et al. 2022

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

show abstract

“…Much focus has been given to the potential roles nucleic acids play in disease pathology (see Table ); however, there is an exciting potential that their activity can be exploited in biotechnology. It has already been shown that tRNA can provide chaperone function for the folding and assembly of monomers into virus-like particles in vaccine technology …”

Section: Discussionmentioning

confidence: 99%

Roles of Nucleic Acids in Protein Folding, Aggregation, and Disease

Litberg,

Horowitz

2024

ACS Chem. Biol.

View full text Add to dashboard Cite

“…Recombinant protein antigens are usually poorly immunogenic because of their small size. The oligomeric assembly of monomeric antigens in a highly repetitive manner (as VLPs or nanoparticles) is the key to activate B-cells (42)(43)(44). Thus, particulate formation and/or adjuvant usage with antigens is crucial for improving the immunogenicity of subunit vaccines (45).…”

Section: Discussionmentioning

confidence: 99%

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

et al. 2021

Self Cite

View full text Add to dashboard Cite

Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have been documented to have irreversible virucidal function, with the possible applicability in the inactivated viral vaccine platform. In a mouse model, the coadministration of epigallocatechin-3-gallate (EGCG) with influenza hemagglutinin (HA) antigens induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge. Adjuvant effects were observed for all types of HA antigens, including recombinant full-length HA and HA1 globular domain, and egg-derived inactivated split influenza vaccines. The combination of alum and EGCG further increased neutralizing (NT) antibody titers with the corresponding hemagglutination inhibition (HI) titers, demonstrating a dose-sparing effect. Remarkably, EGCG induced immunoglobulin isotype switching from IgG1 to IgG2a (approximately >64–700 fold increase), exerting a more balanced TH1/TH2 response compared to alum. The upregulation of IgG2a correlated with significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) function (approximately 14 fold increase), providing a potent effector-mediated protection in addition to NT and HI. As the first report on a novel class of vaccine adjuvants with built-in virucidal activities, the results of this study will help improve the efficacy and safety of vaccines for pandemic preparedness.

show abstract

RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform

Cited by 18 publications

References 71 publications

Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic

Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic

Roles of Nucleic Acids in Protein Folding, Aggregation, and Disease

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Contact Info

Product

Resources

About